Advertisement

Cancer Causes & Control

, Volume 29, Issue 1, pp 103–114 | Cite as

Factors related to longitudinal adherence in colorectal cancer screening: qualitative research findings

  • Llucia Benito
  • Albert Farre
  • Gemma Binefa
  • Carmen Vidal
  • Angels Cardona
  • Margarita Pla
  • Montse GarcíaEmail author
Original paper

Abstract

Background

The effectiveness of screening in colorectal cancer prevention depends on sustained participation rates. The objective of this study was to explore factors related to the longitudinal adherence of screening behavior in the context of a biennial population-based cancer screening program.

Methods

Eight focus groups were conducted with individuals who were invited two or three consecutive times to a population-based colorectal cancer screening program using a fecal occult blood test and who agreed to participate in the program at least once (n = 45). The criteria used to select the study members included adherence to fecal occult blood test maintenance, factors regarding their initial participation in the colorectal cancer screening, sex, and contextual educational level.

Results

The participants expressed a high level of satisfaction with the program; however, they showed a low level of understanding with respect to cancer screening. Consulting a general practitioner was cited by all participants as an important factor that mediated their final decision or influenced their behavior as a whole with regard to the program. Fear played a different role in the screening behavior for regular and irregular adherent participants. In the adherent participants, fear facilitated their continued participation in the screening program, whereas for the irregular participants, fear led them to avoid or refuse further screening. Having a close person diagnosed with colorectal cancer was a facilitator for the regular adherent participants. The irregular adherent participants showed some relaxation with respect to screening after a negative result and considered that further screening was no longer necessary.

Conclusion

Considering the importance of primary healthcare professionals in the decision regarding sustained participation, it is important to better engage them with cancer screening programs, as well as improve the communication channels to provide accurate and balanced information for both health professionals and individuals.

Keywords

Colorectal cancer Participation Mass screening Longitudinal adherence Barriers Qualitative study 

Notes

Acknowledgments

The funding was supported by Department of Health of Catalonia (Grant No. SLT002/16/00407).

References

  1. 1.
    Amonkar MM, Madhavan S, Rosenbluth SA, Simon KJ (1999) Barriers and facilitators to providing common preventive screening services in managed care settings. J Commun Health 24:229–247CrossRefGoogle Scholar
  2. 2.
    Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, Parkin DM, Wardle J, Duffy SW, Cuzick J (2010) Once only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375:1624–1633CrossRefPubMedGoogle Scholar
  3. 3.
    Beeker C, Kraft JM, Southwell BG, Jorgensen CM (2000) Colorectal cancer screening in older men and women: qualitative research findings and implications for intervention. J Commun Health 25:263–278CrossRefGoogle Scholar
  4. 4.
    Braun V, Clarke V (2006) Using thematic analysis in psychology. Qual Res Psychol 3:77–101CrossRefGoogle Scholar
  5. 5.
    Brenner H, Stock C, Hoffmeister M (2014) Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. Br Med J 348:g2467CrossRefGoogle Scholar
  6. 6.
    Brenner H, Chang-Claude J, Jansen L, Knebel P, Stock C, Hoffmeister M (2014) Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. Gastroenterology 146:709–717CrossRefPubMedGoogle Scholar
  7. 7.
    Bridou M, Aguerre C, Gimenes G, Kubiszewski V, Le Gall A, Potard C, Sorel O, Reveillere C (2013) Psychological barriers and facilitators of colorectal cancer screening: a french qualitative study. Health Psychol Res 1:e22CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Bulliard JL, De Landtsheer JP, Levi F (2004) Reattendance in the Swiss mammography screening pilot programme. J Med Screen 11:59Y64CrossRefGoogle Scholar
  9. 9.
    Calazel-Benque A, Viguier J, Roussel C, Pivot X, Eisinger F, Blay JY, Coscas Y, Morère JF (2011) Organized colorectal cancer screening programmes: how to optimize efficiency in the general population. Eur J Cancer Prev 20:S20–S25CrossRefPubMedGoogle Scholar
  10. 10.
    Clemow L, Costanza ME, Haddad WP, Luckmann R, White MJ, Klaus D, Stoddard AM (2000) Underutilizers of mammography screening today: characteristics of women planning, undecided about, and not planning a mammogram. Ann Behav Med 22:80–88CrossRefPubMedGoogle Scholar
  11. 11.
    Commission of the European Communities (CEC) (2003) Proposal for a council recommendation on cancer screening. 2003/0093 (CNS). Commission of the European Communities (CEC), BrusselsGoogle Scholar
  12. 12.
    Crotta S, Segnan N, Paganin S, Dagnes B, Rosset R, Senore C (2012) High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol 10:633–638CrossRefPubMedGoogle Scholar
  13. 13.
    Denis B, Gendre I, Perrin P (2015) Participation in four rounds of a French colorectal cancer screening programme with guaiac faecal occult blood test: a population-based open cohort study. J Med Screen 22:76–82CrossRefPubMedGoogle Scholar
  14. 14.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Canc 49:1374–1403CrossRefGoogle Scholar
  15. 15.
    García M, Borràs JM, Milà N, Espinàs JA, Binefa G, Fernández E, Farré A, Pla M, Cardona A, Moreno V (2011) Factors associated with initial participation in a population-based screening for colorectal cancer in Catalonia, Spain: a mixed-methods study. Prev Med 52:265–267PubMedGoogle Scholar
  16. 16.
    Gellad ZF, Stechuchak KM, Fisher DA, Olsen MK, McDuffie JR, Østbye T, Yancy WS (2011) Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality. Am J Gastroenterol 106:1125–1134CrossRefPubMedGoogle Scholar
  17. 17.
    Glaser BG (1965) The constant comparative method of qualitative analysis. Soc Probl 5(12):436–445CrossRefGoogle Scholar
  18. 18.
    Goel V, Gray R, Chart P, Fitch M, Saibil F, Zdanowicz Y (2004) Perspectives on colorectal cancer screening: a focus group study. Health Expect 7:51–60CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Grazzini G, Castiglione G, Ciabattoni C, Franceschini F, Giorgi D, Gozzi S, Mantellini P, Lopane P, Perco M, Rubeca T, Salvadori P, Visioli CB, Zappa M (2004) Colorectal cancer screening programme by faecal occult blood test in Tuscany: first round results. Eur J Cancer Prev 13:19–26CrossRefPubMedGoogle Scholar
  20. 20.
    Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM (1996) Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348:1472–1477CrossRefPubMedGoogle Scholar
  21. 21.
    Hewitson P, Glasziou P, Watson E, Towler B, Irwig L (2008) Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 103:1541–1549CrossRefPubMedGoogle Scholar
  22. 22.
    Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JC, van der Togt AC, Habbema JD, Kuipers EJ (2010) Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 59:62–68CrossRefPubMedGoogle Scholar
  23. 23.
    Honein-AbouHaidar GN, Kastner M, Vuong V, Perrier L, Daly C, Rabeneck L, Straus S, Baxter NN (2016) Systematic review and meta-study synthesis of qualitative studies evaluating facilitators and barriers to participation in colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 25:907–917CrossRefPubMedGoogle Scholar
  24. 24.
    Jandorf L, Ellison J, Villagra C, Winkel G, Varela A, Quintero-Canetti Z, Castillo A, Thélémaque L, King S, Duhamel K (2010) Understanding the barriers and facilitators of colorectal cancer screening among low income immigrant Hispanics. J Immigr Minor Health 12:462–469CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Jones RM, Devers KJ, Kuzel AJ, Woolf SH (2010) Patient-reported barriers to colorectal cancer screening: a mixed-methods analysis. Am Journal Prev Me 38:508–516CrossRefGoogle Scholar
  26. 26.
    Kapidzic A, Grobbee EJ, Hol L, van Roon AH, van Vuuren AJ, Spijker W, Izelaar K, van Ballegooijen M, Kuipers EJ, van Leerdam ME (2014) Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am J Gastroenterol 109:1257–1264CrossRefPubMedGoogle Scholar
  27. 27.
    Khalid-de Bakker C, Jonkers D, Smits K, Mesters I, Masclee A, Stockbrügger R (2011) Participation in colorectal cancer screening trials after first-time invitation: a systematic review. Endoscopy 43:1059–1086CrossRefPubMedGoogle Scholar
  28. 28.
    Krönborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O (1996) Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348:1467–1471CrossRefPubMedGoogle Scholar
  29. 29.
    Leuraud K, Jezewski-Serra D, Viguier J, Salines E (2013) Colorectal cancer screening by guaiac faecal occult blood test in France: Evaluation of the programme two years after launching. Cancer Epidemiol 37:959–967CrossRefPubMedGoogle Scholar
  30. 30.
    L’Hospitalet de Llobregat City Council (2010) http://www.l-h.cat/laciutat/265243_1.aspx?id=1. Accessed 25 June 2010
  31. 31.
    Lo SH, Halloran S, Snowball J, Seaman H, Wardle J, von Wagner C (2014) Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme. Gut 64:282–291CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Lo SH, Halloran S, Snowball J, Seaman H, Wardle J, Von Wagner C (2015) Predictors of repeat participation in the NHS bowel cancer screening programme. BJC 112:199–206CrossRefPubMedGoogle Scholar
  33. 33.
    Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM (2000) The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 343:1603–1607CrossRefPubMedGoogle Scholar
  34. 34.
    Marshall G (1994) A comparative study of re-attenders and non-re-attenders for second triennial National Breast Screening Programme appointments. J Public Health Med 16:79Y86CrossRefGoogle Scholar
  35. 35.
    Maxwell A, Roshan B, Bradford C (1996) Predictors of interval mammography screening: results of a longitudinal study. J Womens Health 5:343Y349CrossRefGoogle Scholar
  36. 36.
    Mays N, Pope C (1995) Qualitative research: observational methods in health care settings. BMJ 311:182–184CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Milà N, García M, Binefa G, Borràs JM, Espinàs JA, Moreno V (2012) Adherence to a population-based colorectal cancer screening program in Catalonia (Spain), 2000–2008. Gac Sanit 26:217–222CrossRefPubMedGoogle Scholar
  38. 38.
    Myers RE, Balshem AM, Wolf TA, Ross EA, Millner L (1993) Adherence to continuous screening for colorectal neoplasia. Med Care 31:508–519CrossRefPubMedGoogle Scholar
  39. 39.
    Muhr T (2004) ATLAS.ti 5.0 [Version 5:]. ATLAS.ti scientific software development GmbH, Berlin, Germany. Available from http://www.atlasti.com/
  40. 40.
    Nishihara R, Ogino S, Chan AT (2013) Colorectal-cancer incidence and mortality after screening. N Engl J Med 369:2355CrossRefPubMedGoogle Scholar
  41. 41.
    O’Malley AS, Forrest CB, Mandelblatt J (2002) Adherence of low-income women to cancer screening recommendations. J Gen Intern Med 17:144–154CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Orton M, Fitzpatrick R, Fuller A, Mant D, Mlynek C, Thorogood M (1991) Factors affecting women’s response to an invitation to attend for a second breast cancer screening examination. Br J Gen Pract 41:320Y322Google Scholar
  43. 43.
    Palmer CK, Thomas MC, von Wagner C, Raine R (2014) Reasons for non-uptake and subsequent participation in the NHS Bowel Cancer Screening Programme: a qualitative study. Br J Cancer 110:1705–1711CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Panidi, Ksenia and Job Market. Ostrich effect in health care decisions: theory and empirical evidence. Diss. Dissertation (2014)Google Scholar
  45. 45.
    Papin-Lefebvre F, Guillaume E, Moutel G, Launoy G, Berchi C (2017) General practitioners’ preferences with regard to colorectal cancer screening organisation Colon cancer screening medico-legal aspects. Health Policy 121:1079–1084Google Scholar
  46. 46.
    Parkin DM, Tappenden P, Olsen AH, Patnick J, Sasieni P (2008) Predicting the impact of the screening programme for colorectal cancer in the UK. J Med Screen 15:163–174CrossRefPubMedGoogle Scholar
  47. 47.
    Patton MQ (2002) Qualitative research and evaluation methods, 3rd edn. SAGE, LondonGoogle Scholar
  48. 48.
    Peipins LA, Shapiro JA, Bobo JK, Berkowitz Z (2006) Impact of women’s experiences during mammography on adherence to rescreening (United States). Cancer Causes Control 17:439Y447CrossRefGoogle Scholar
  49. 49.
    Peris M, Espinas JA, Muñoz L, Navarro M, Binefa G, Borras JM (2007) Lessons learnt from a population-based pilot program for colorectal cancer screening in Catalonia (Spain). J Med Screen 14:81–86CrossRefPubMedGoogle Scholar
  50. 50.
    Ponti A, Anttila A, Ronco G, Senore C (2017) Cancer Screening in the European Union Report on the implementation of the Council Recommendation on cancer screening. Cancer screening in the European Union. Report on the implementation of the Council Recommendation on cancer screening (reprint May 2017)Google Scholar
  51. 51.
    Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, Fouad MN, Isaacs C, Johnson CC, Reding DJ, O’Brien B, Carrick DM, Wright P, Riley TL, Purdue MP, Izmirlian G, Kramer BS, Miller AB, Gohagan JK, Prorok PC, Berg CD, PLCO Project Team (2012) Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 366:2345–2357CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, Andreoni B, Arrigoni A, Bisanti L, Casella C, Crosta C, Falcini F, Ferrero F, Giacomin A, Giuliani O, Santarelli A, Visioli CB, Zanetti R, Atkin WS, Senore C, SCORE Working Group (2011) Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial-SCORE. J Natl Cancer Inst. 103:1310–1322CrossRefPubMedGoogle Scholar
  53. 53.
    Steele RJ, McClements PL, Libby G, Carey FA, Fraser CG (2014) Patterns of uptake in a biennial faecal occult blood test screening programme for colorectal cancer. Colorectal Dis 16:28–32CrossRefPubMedGoogle Scholar
  54. 54.
    Tinmouth J, Lansdorp-Vogelaar I, Allison JE (2015) Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. Gut 64:1327–1337CrossRefPubMedGoogle Scholar
  55. 55.
    van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E (2008) Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135:82–90CrossRefPubMedGoogle Scholar
  56. 56.
    van der Vlugt M, Grobbee EJ, Bossuyt PM, Bongers E, Spijker W, Kuipers EJ, Lansdorp-Vogelaar I, Essink-Bot ML, Spaander MC, Dekker E (2017) Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening. Br J Cancer 116:44–49CrossRefPubMedGoogle Scholar
  57. 57.
    von Euler-Chelpin M, Brasso K, Lynge E (2010) Determinants of participation in colorectal cancer screening with faecal occult blood testing. J Public Health 32:395–405CrossRefGoogle Scholar
  58. 58.
    von Karsa L, Anttila A, Ronco G, Ponti A, Malila N, Arbyn M, Segnan N, Castillo-Beltran M, Boniol M, Ferlay J, Hery C, Sauvaget C, Voti L, Autier P (2008) Cancer screening in the European Union. Report on the implementation of the Council Recommendation on Cancer Screening. International Agency for Research of Cancer, European CommunitiesGoogle Scholar
  59. 59.
    von Wagner C, Baio G, Raine R, Snowball J, Morris S, Atkin W, Obichere A, Handley G, Logan RF, Rainbow S, Smith S, Halloran S, Wardle J (2011) Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England. Int J Epidemiol 40:712–718Google Scholar
  60. 60.
    Vrinten C, Waller J, von Wagner C, Wardle J (2015) Cancer fear: facilitator and deterrent to participation in colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 24:400–405CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Weller DP, Patnick J, McIntosh HM, Dietrich AJ (2009) Uptake in cancer screening programmes. Lancet Oncol 10:693–699CrossRefPubMedGoogle Scholar
  62. 62.
    Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG (1993) Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 85:1311–1318CrossRefPubMedGoogle Scholar
  63. 63.
    Wong RK, Wong ML, Chan YH, Feng Z, Wai CT, Yeoh KG (2013) Gender differences in predictors of colorectal cancer screening uptake: a national cross-sectional study based on the health belief model. BMC Public Health 13:677–688CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Wools A, Dapper EA, de Leeuw JR (2016) Colorectal cancer screening participation: a systematic review. Eur J Public Health 26:158–168CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Cancer Prevention and Control ProgramCatalan Institute of OncologyHospitalet de Llobregat (Barcelona)Spain
  2. 2.Institute of Biomedical ResearchIDIBELLHospitalet de Llobregat (Barcelona)Spain
  3. 3.Fundamental Care and Medical-Surgical Nursing Department, School of NursingUniversity of BarcelonaHospitalet de Llobregat (Barcelona)Spain
  4. 4.Institute of Applied Health ResearchUniversity of BirminghamEdgbastonUK
  5. 5.AreaQ Evaluation and Qualitative Research SLBarcelonaSpain
  6. 6.Public Health, Mental Health and Perinatal Nursing Department, School of NursingUniversity of BarcelonaHospitalet de Llobregat (Barcelona)Spain

Personalised recommendations